Overview

Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease

Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Safety and efficacy of AADC gene transfer in participants with Parkinson's disease.
Phase:
Phase 1
Details
Lead Sponsor:
Neurocrine Biosciences
Voyager Therapeutics
Collaborator:
Voyager Therapeutics